Newly designed, flexible manufacturing facilities give contract manufacturers the potential to quickly respond to the capacity needs of a growing market. Pharmaceutical and biotechnology companies need look no further than Hospira's One 2 One(r) global pharmaceutical services to see the difference.
Over the past five years, a growing pipeline of new products, particularly biologics, has increased capacity demands for contract manufacturers that produce lyophilised injectable pharmaceuticals. With traditionally designed facilities, many manufacturers must stop production and tear down walls in order to increase capacity - interrupting supply and delaying product delivery to customers.
Hospira's One 2 One, a leading injectable contract manufacturer, is changing the conventional manufacturing paradigm at its recently expanded facility in McPherson, Kansas, USA. At the site, Hospira makes a variety of injectable drugs in several different delivery systems for both its hospital and contract manufacturing customers. With a long track record of CGMP compliance, the McPherson team also specialises in the filling, lyophilisation and finishing of parenteral biologic products.
With a state-of-the-art design and 80,000ft2 of additional manufacturing space at the McPherson site, Hospira can add capacity to meet One 2 One customer needs without sacrificing service or quality. Hospira does this through a unique two-step approach. Firstly, the facility expansion was built with room to grow along with customers' needs, without necessitating the use of 'bricks and mortar'.
Secondly, the site was engineered to allow modules to be added on as necessary. The McPherson facility uses leading isolation technologies to create the sterile environment needed for working with biologics and traditional pharmaceuticals. The facility also offers autoloading lyophilisers, helping to provide a greater degree of quality assurance. Given this approach, the site can accommodate expanded filling and lyophilisation units - without any interruption to the ongoing manufacturing.
Ensuring adequate product supply is just one of the key factors pharmaceutical and biotechnology companies should explore when looking for a contract manufacturing partner. Companies should also assess the experience and resources the manufacturer makes available to them.
Hospira has more than 70 years of experience in developing parenteral agents and more than 20 years in contract manufacturing - giving the company one of the most experienced track records in the business. The company has made significant investments to better serve customer needs now and well into the future, both domestically and abroad.
The McPherson facility is one of five Hospira facilities equipped to accommodate a wide range of injectable contract manufacturing needs. The company also offers One 2 One manufacturing capabilities in Rocky Mount, Clayton and Austin, USA, as well as Liscate, Italy.
Through its One 2 One business, Hospira provides a full range of manufacturing expertise in areas such as analytical, pharmacy, regulatory and microbiology. Client companies can choose from a number of injectable delivery systems including small- and large-volume parenterals, flexible containers, pre-filled syringes and cartridges.
Hospira, Inc is a global speciality pharmaceutical and medication delivery company dedicated to Advancing Wellness(tm) by developing, manufacturing and marketing products that help improve the productivity, safety and efficacy of patient care. With 70 years of service to the hospital industry, Hospira's portfolio includes one of the industry's broadest lines of generic acute-care injectables, which help address the high cost of proprietary pharmaceuticals in hospitals; integrated solutions for medication management and infusion therapy; and the leading US injectable contract manufacturing business. Headquartered in Lake Forest, Illinois, Hospira has approximately 13,000 employees and 14 manufacturing facilities worldwide.